A research brand for one bacterium and eight conditions.
Welyon publishes investigation guides, manufactures a non-invasive testing kit, and runs a physician-supervised protocol. It exists because the literature on H. pylori has moved faster than the standard workup.
Close the gap between documented mechanism and routine practice.
Roughly one in three Americans carry H. pylori. The peer-reviewed literature has — slowly, across thirty years — associated this single bacterium with eight clinically distinct presentations, from refractory iron deficiency to chronic spontaneous urticaria. The mechanisms are increasingly characterised. The literature is publicly available. The diagnostic step required to act on it costs less than a single visit to a specialist.
And yet the standard workup for each of those eight conditions only tests for H. pylori when the symptom is digestive. The literature has moved. The order sets, mostly, have not.
That is the whole project. Welyon does not invent mechanism, does not promise resolution, does not sell a wellness lifestyle. It publishes what the literature already says, gives readers the language to ask sharper questions, and stands behind a testing pathway when the conversation calls for one.
Every claim, tagged inline. Every tier, defined publicly.
The investigation series spans claims that are well-replicated and claims that are early-stage. Treating those two categories with the same visual weight would be a trust failure. So we don't. Every claim across the eight guides carries one of three tiers — Strong, Moderate, or Exploratory — applied inline at the point of claim, and again in the citation list at the back of the PDF.
The rubric is applied identically regardless of whether the resulting investigation routes a reader toward — or away from — Welyon's testing kit and protocol. Editorial grading is independent of commercial outcome. That independence is the trust contract.
Multiple peer-reviewed studies in agreement; replicated in independent cohorts; mechanism characterised. The case for investigating is well-established.
Consistent literature, but cohort scale is limited or the mechanism is only partially characterised. The case is plausible and worth pursuing as part of a structured workup.
Plausible mechanism with early-stage or pilot-cohort evidence. The case for investigating, not the case for concluding. Flagged honestly on the cover and inline.
A board, named publicly, in formation.
Welyon is assembling a scientific advisory board of clinicians and researchers with expertise in gastroenterology, infectious disease, and evidence-based medicine. Advisor names and affiliations will be listed here upon confirmation.
The board's first job is review: of the investigation guides, of the testing pathway, and of the rubric used to grade evidence across the series. The second is governance: ensuring the editorial grading rubric stays applied identically, regardless of commercial outcome.
Six advisor positions are being filled across the specialties listed below. Letters of interest are reviewed monthly.
Clinical & research scope: H. pylori diagnostic methods, refractory presentations, eradication protocols, and post-eradication surveillance.
Clinical & research scope: chronic bacterial colonisation, host–pathogen dynamics, antibiotic stewardship in eradication regimens.
Clinical & research scope: study quality grading, meta-analysis methodology, and editorial governance of the three-tier evidence rubric.
Clinical & research scope: iron homeostasis, hepcidin signalling, B12 absorption pathways, and refractory anaemia presentations.
Clinical & research scope: thyroid autoimmunity, metabolic dysregulation, and the gastric–endocrine axis literature.
Clinical & research scope: cutaneous expression of systemic inflammation, chronic urticaria, rosacea pathophysiology, mast cell biology.
If this is your field.
If you are a clinician or researcher working in H. pylori-associated disease — particularly in the six specialties named on the previous page — and you are interested in contributing to Welyon's evidence architecture, we would like to hear from you.
Letters of interest are reviewed monthly. No CV format is required; a paragraph naming your current institution, your research interests, and the specialty you'd like to advise on is enough to start the conversation.
Commercial interest disclosure
Welyon produces the at-home H. pylori testing kit and the physician-supervised Foundation Protocol referenced in these guides. The investigation guides are commercial publications. This commercial interest is disclosed on every guide cover, every checkout page, and in the footer of this site. The investigation steps described in the guides would apply equally if neither product existed.
Editorial independence
Evidence grading across the series follows a single rubric, applied identically regardless of whether the resulting investigation routes a reader toward — or away from — Welyon's testing kit or protocol. Reviewer names will appear in the front matter of each guide upon confirmation of the advisory board. No claims are softened or strengthened for commercial benefit.